Treatments for symptomatic uterine fibroids are continuing to develop, with new drugs on the horizon.
Leiomyomas of the uterus, more commonly known as fibroids, are benign tumours of the smooth muscle and connective tissues of the uterus.
They are said to have a lifetime incidence of around 60-70%; but small, subclinical tumours may be even more common.1
There is also a familial predisposition: first-degree relatives of women with clinical fibroids are more than twice as likely to develop them as women with unaffected relatives.
Other risk factors include early age of menarche, nulliparity and obesity.
Although for most women uterine fibroids are completely asymptomatic, about 20-30% of women with uterine fibroids experience symptoms.
These patients warrant further investigation and advice about the many, increasing management options.